Singapore Volition signs Memorandum of Understanding with the National Taiwan University to Conduct Two Large Clinical Studies

ISNES, Belgium, Nov. 10, 2017 /PRNewswire/ -- Singapore Volition Pte. Ltd, a wholly-owned subsidiary of VolitionRx Limited (NYSE American: VNRX) ("Volition"), has entered into a Memorandum of Understanding ("MOU") with the National Taiwan University ("NTU") to conduct two large colorectal cancer (CRC) research studies across the Asia Pacific Region, totaling approximately 7,000 patient samples. Subject to agreement on the terms and conditions, the Parties intend to sign a binding CRC Study Agreement in the first quarter of 2018.  

"The signing of this MOU is a good start for Volition in the Asia Pacific Region" commented Dr. Jasmine Kway, Volition's Vice President of Asia. "We are fortunate and delighted to be working with a renowned institution and Professor Han-Mo Chiu, a prominent thought leader. This large-scale study will be low cost in line with Volition's other great value studies such as the 13,500-subject study in the U.S. and the ongoing 30,000-subject prospective study in Europe and demonstrates our commitment to conducting large trials worldwide to drive the acceptance of our products."

The first trial will be a large scale multi-country, multi-center and multi-ethnic study in the Asia Pacific Region, including 5,000 asymptomatic colorectal cancer screening subjects. The second trial will include up to 2,000 symptomatic colorectal cancer patients. These studies are being conducted to test and validate Volition's proprietary Nu.QTM platform for the detection and diagnosis of colorectal cancer for marketing, rather than for regulatory purposes.

The studies will be under the supervision of Professor Han-Mo Chiu, Clinical Professor, Department of Internal Medicine of NTU who will be the Principal Investigator for both trials. Prof. Chiu is highly regarded and widely published in this field, with many awards and achievements to his name. Professor Chiu commented, "The early detection of colorectal cancer could benefit the survival rate of patients significantly. There is a clear need for a product which not only has high accuracy but is also easy to use and affordable. I look forward to proceeding with the collaboration with Volition on these projects."

About the National Taiwan University

NTU is one of the most prestigious universities in the world and is the top university in Taiwan. The University has a wide network of partners and collaborators and plays a leading role in education and research. The University has four university level research centers, with an overall student population of 33,000.

About Volition

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.

As cancer screening programs become more widespread, Volition's products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.

Volition's research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

For more information about Volition, visit Volition's website ( or connect with us via:


The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document.  The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

Media / Investor Contacts

Louise Day, Volition

+44 (0)7557 774620

Scott Powell, Volition

+1 (646) 650 1351

Tirth Patel, Edison Advisors

+1 (646) 653 7035

Rachel Carroll, Edison Advisors

+44 (0)20 3077 5711

Safe Harbor Statement

Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of Volition's bodily-fluid-based diagnostic tests as well as Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, if Volition fails to develop and commercialize diagnostic products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the clinical IVD market; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic products Volition might develop; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics®, NuQ®, Nu.QTM and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

View original content:

SOURCE VolitionRx Ltd